To evaluate whether H3K9la inhibition would sensitize GBM cells to TMZ, we reduced H3K9la levels in TMZ‐resistant (TR) cells, using shRNAs targeting LDHA and LDHB to attenuate lactate and H3K9la levels (Figure2A). The gene discussed is LDHA; the disease is glioblastoma.